These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31892925)

  • 41. Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
    Wahid A; Ahmad N; Ghafoor A; Latif A; Saleem F; Khan S; Atif M; Iqbal Q
    Am J Trop Med Hyg; 2021 Mar; 104(5):1784-1791. PubMed ID: 33724924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
    Nie Q; Tao L; Li Y; Chen N; Chen H; Zhou Y; Wang Y; Chen H; Tang Q; Wang X; Huang C; Yang C
    Int J Infect Dis; 2022 Feb; 115():142-148. PubMed ID: 34861398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
    Gezae KE; Abebe HT; Gebretsadik LG
    BMC Infect Dis; 2019 Feb; 19(1):107. PubMed ID: 30717705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brazilian experience in the management of multidrug-resistance.
    de Melo FA
    Rev Port Pneumol; 2010 Jan; 16SA():S11-20. PubMed ID: 25965924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Loss to follow-up among patients receiving anti-tuberculosis treatment, Haiti, 2011-2015.
    Schnaubelt ER; Charles M; Richard M; Fitter DL; Morose W; Cegielski JP
    Public Health Action; 2018 Dec; 8(4):154-161. PubMed ID: 30775274
    [No Abstract]   [Full Text] [Related]  

  • 47. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determinants of treatment outcomes in patients with multidrug-resistant TB.
    Burhan E; Soepandi PZ; Isbaniah F; Damayanti K; Edwar SQ; Maruli MF; Ralena NA; Susanto AD
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):126-132. PubMed ID: 35086624
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study.
    Mollel E; Lekule I; Lynen L; Decroo T
    Int Health; 2019 Nov; 11(6):520-527. PubMed ID: 30806660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.
    Mohr E; Daniels J; Beko B; Isaakidis P; Cox V; Steele SJ; Muller O; Snyman L; De Azevedo V; Shroufi A; Trivino Duran L; Hughes J
    PLoS One; 2017; 12(5):e0178054. PubMed ID: 28542441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-drug resistant and rifampin-resistant tuberculosis in transplant recipients.
    Abad CLR; Razonable RR
    Transpl Infect Dis; 2023 Aug; 25(4):e14088. PubMed ID: 37335213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia.
    Kibuule D; Aiases P; Ruswa N; Rennie TW; Verbeeck RK; Godman B; Mubita M
    ERJ Open Res; 2020 Jan; 6(1):. PubMed ID: 32201689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients: A 6-Year Retrospective Study from Pakistan.
    Khan FU; Rehman AU; Khan FU; Hayat K; Khan A; Ahmad N; Chang J; Malik UR; Fang Y
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment outcomes of TB-infected individuals attending public sector primary care clinics in rural Liberia from 2015 to 2017: a retrospective cohort study.
    Wickett E; Peralta-Santos A; Beste J; Micikas M; Toe F; Rogers J; Jabateh L; Wagenaar BH
    Trop Med Int Health; 2018 May; 23(5):549-557. PubMed ID: 29524302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil.
    Fregona G; Cosme LB; Moreira CMM; Bussular JL; Dettoni VDV; Dalcolmo MP; Zandonade E; Maciel ELN
    Rev Saude Publica; 2017 Apr; 51(0):41. PubMed ID: 28489185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV-Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial.
    Yende-Zuma N; Naidoo K
    J Acquir Immune Defic Syndr; 2016 Aug; 72(4):430-6. PubMed ID: 26990824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India.
    Deshmukh RD; Dhande DJ; Sachdeva KS; Sreenivas A; Kumar AM; Satyanarayana S; Parmar M; Moonan PK; Lo TQ
    PLoS One; 2015; 10(8):e0135802. PubMed ID: 26301748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.